Maxime Ranger Email and Phone Number

Q: What is Maxime Ranger's email address?

Maxime Ranger's email address is maxime@vandero.vc

Q: What is Maxime Ranger's direct phone number?

Maxime Ranger's direct phone number is +15148259035

PhD MBA | Startup company creator | Life sciences at @ Neurenati

Maxime Ranger's Location

Blainville, Quebec, Canada, Canada

Maxime Ranger's Contact Details

Maxime Ranger work email

Maxime Ranger personal email

n/a

Maxime Ranger phone numbers

About Maxime Ranger

Serial entrepreneur who turned into venture capitalist in the life science space, specialized in the drug development: oncology, hepatology, gastroenterology and metabolic conditions, such as NASH, Prader-Willi Syndrome, type-2 diabetes and obesity. MBA, Ph.D. chemist with a scientific background in Material Sciences, more particularly in polymer chemistry. Two postdoc internships oriented to drug delivery, formulation development and nanolithography. Experience now extended to due diligence investigation, drug hunting and start-up financing. Co-authors of 30+ scientific publications in international peer-reviewed journals and co-inventors of 9 PCT-patented technologies.Specialties: CMC, formulation development, drug delivery, IND-enabling preclinical studies, clinical development strategies (Phase I & II). Pre-Seed, Seed, Series A/B Fundraising, Corporate affairs, licensing activities and IP strategy.

Maxime Ranger's Current Company Details

Neurenati

View

PhD MBA | Startup company creator | Life sciences

Maxime Ranger Work Experience Details

Chief Executive Officer

Neurenati Sep 2023 - Present

We have a therapeutic option ! Hirschsprung disease (HSCR) is a deadly birth defect affecting 1/5000 children. These children are missing innervation from the enteric nervous system (ENS), resulting in severe constipation and a high risk of bacterial translocation into blood causing premature death. Surgery to remove ENS-devoid bowel is generally life-saving but many children with HSCR continue to have severe problems after surgery, especially with enterocolitis.

View
Cofounder - Ceo

Numbio Therapeutics Dec 2023 - Present

Biotech startup focusing on tau-related neuropathies with first indication targeted is ophthalmology with glaucoma and macular degeneration.

View
Senior Business / Scientific Advisor & Investor

Néolys Pharma Nov 2023 - Present

Neolys Pharma develops novel orally-administered anticancer drugs for diverse drug-resistant cancers. Spin-out company from Laval University, with the support of Axelys.

View
Senior Business Advisor

Obaris Jul 2023 - Present

OBaris develops new ways of drug delivery through the mouth mucosa.

View
Senior Business Advisor

Matrix Innovation Inc. Jan 2023 - Present

Quebec, Qc, Ca

Developing novel anti-infectious drugs

View
Asset Valuation Expert - Drug Development Strategist

Gestion Mrim Inc Jan 2023 - Present

Consultant for the following companies or VC funds: - Axelys (Montreal, Canada) - Biossil (Toronto, Canada) - HDAX (Toronto, Canada) - OligoMedic (Montreal, Canada) - Early-stage life science fund - undisclosed (Montreal, Canada)Privately-owned, consulting firm. Helping VC funds during fundraising. Accepting mandates to determine asset valuations, for M&A and fair market valuation during annual audit, using risk-adjusted, cost-based, market-based and/or income-based valuation models. Moreover, giving assistance for fundraising seed/Series A/Series B rounds with biotech startups.

View
Adjunct Professor, Pharmacy

Université De Montréal May 2002 - Present

Montréal, Qc, Ca

Mandate renewed up to 2025. Chairman & internal jury member of thesis defences. Progress Report Committee member for Ph.D. students. Giving lectures from time to time.

View
Seed Investor

Giiant Pharma Inc. Feb 2021 - Present

Montreal, Quebec, Ca

View
Executive Chairman

Giiant Pharma Inc. Jan 2023 - Dec 2023

Montreal, Quebec, Ca

Advisor to the CEO, Christophe Mellon.EXIT - Worldwide exclusive license and partnership agreement signed with Palisade Bio. Cost sharing up to IND (with major contribution of the Partner). Projected IRR > 22% with a multiple > 2.8X for investors. Distribution will reach founders’ common stock.Shareholders: Founders, Employees, Genesys Capital, Fonds FTQ, Theodorus, CQDM, AmorChem, Amplitude, Anges Québec & AQC Capital, plus various angel individuals and key management investment.

View
Chief Executive Officer

Giiant Pharma Inc. Jun 2020 - Jan 2023

Montreal, Quebec, Ca

CEO and chairman of the Board. Gastroenterology(GI)-focused company with a gut-restricted, colon-specific PDE4 inhibitor prodrug as lead program, to treat and manage inflammatory bowel diseases (IBD). The Company has a drug hunting club approach to identify and acquire GI focused assets in order to build a GI franchise in Precision Delivery.

View
Président Du Conseil D’Administration

Théâtre Denise-Pelletier Sep 2019 - Sep 2024

Montréal, Québec, Ca

Cette section est en français, car les pièces qui s’y déroulent sont dans la langue de Molière! Direction artistique : Claude Poissant. Directeur général : Stéphanie Laurin

View
Cofounder And Co-Chair

Sweet Pharma Day Jan 2019 - Sep 2024

Westmount, Quebec, Ca

I remain ambassador of the event. First edition was April 2019 and the second one was organized October, 2021. The event remains an invitation-only to be organized in the Greater Montreal area. Second edition was virtual due to the covid pandemic. It remained a success. The third edition will be led by BioQuebec.

View
Organizer - Alliance & Partnership (Consultant)

Cqib, Quebec Life Sciences Incubator & Accelerator Jan 2023 - Jul 2024

Laval, Québec, Ca

Working with the CQIB Managing Director for partnership and alliance.

View
Senior Advisor To Ceo

Angany May 2023 - Sep 2023

Québec, Québec, Ca

Assisting the management during the fundraising, with Echelon-Stifel firms’ support. Phase 0/1 clinical stage company specializing in immunotherapy to treat allergies and fight cancers. First indication targeted is cat allergy vaccine, followed by peanut allergy vaccine. Veterinary applications with a signed animal health partner.

View
Founder & Managing Partner

Vandero Ventures Jan 2023 - Sep 2023

The intent is to raise a Seed Fund to support innovative research in life sciences within the Quebec ecosystem.

View
Advisor To Ceo

Inversago Pharma Feb 2021 - Sep 2023

Montreal, Quebec, Ca

EXIT - Inversago was acquired by Novo Nordisk for US$ 1.075B (August 2023).US$ 600M upfront payment plus total milestone payments to be paid, to reach US$ 1.075B Total investment CA$ 150M. Crystallized multiple 5X. Projected IRR > 37% with a multiple > 9X.Shareholders: Founders, Employees, NEA, Forbion Capital, Amgen Ventures, Genesys Capital, Fonds FTQ, AmorChem, adMare BioInnovations, Anges Québec & AQC Capital, plus various angel individuals.

View
Board Observer

Inversago Pharma Feb 2020 - Feb 2021

Montreal, Quebec, Ca

Cofounder. Board Observer representing AmorChem, founding investor. Maintaining an active role on the Board, advising the CEO. Inversago focuses on the development of peripherally-restricted, orally-administered CB1 receptor inverse agonist in rare diseases, like Prader-Willi and lung fibrosis, and type-1 diabetes.

View
Board Member

Inversago Pharma Jul 2018 - Feb 2020

Montreal, Quebec, Ca

Cofounder. Board member representing AmorChem, co-lead investor. Maintaining an active role as Board member, advising the CEO. Inversago focuses on the development of peripherally-restricted, orally-administered CB1 receptor inverse agonist in rare diseases, like Prader-Willi and lung fibrosis, and type-1 diabetes.

View
Advisor To Ceo

Inversago Pharma Jul 2017 - Jul 2018

Montreal, Quebec, Ca

View
Cofounder - Ceo

Inversago Pharma May 2015 - Jul 2017

Montreal, Quebec, Ca

Inversago Pharma is a start-up company focusing two families of novel dual-action, CB1 receptor antagonists / inverse agonists to be developed and used as anti-obesity drugs, including Prader-Willi Syndrome, with the ability to prevent and reverse liver fibrosis. Technology developed by Dr George Kunos at US NIH NIAAA.

View
Venture Partner

Genesys Capital Jan 2022 - Dec 2022

Toronto, Ontario, Ca

Venture Partner at Genesys Capital, a Canadian leading venture capital fund specialized in life sciences, investing equally in medical devices and drug therapeutics.

View
Advisor To Ceo

Semathera Inc Feb 2021 - Dec 2022

Westmount, Quebec, Ca

EXIT - SemaThera signed a worldwide exclusive license with Roche (Febuary 2021). US$ 250M in total milestone payments to be paid. All development cost paid by Roche.Total investment < CA$ 5M. Crystallized multiple: 3.2X. Projected IRR > 38% with a multiple > 50X.Shareholders: Founders, employees, AmorChem and Senju Pharmaceutical.

View
Chairman, Board Of Directors

Semathera Inc Sep 2018 - Feb 2021

Westmount, Quebec, Ca

Chairman of the Board and close advisor to CEO. The Company is currently developing bispecific SEMA3A / VEGF inhibitors (traps) to prevent vascular leakage and damper the inflammation in diabetic macular edema (DME). This novel approach will shift the paradigm to a preventive and active therapy against DME.

View
Board Member

Semathera Inc Sep 2016 - Sep 2018

Westmount, Quebec, Ca

Being CEO until June 2018. SemaThera is a spin-off company from AmorChem Fund 1, which focuses on a novel target, semaphorin 3A (SEMA3A). The Company is currently developing bispecific SEMA3A / VEGF inhibitors (traps) to prevent vascular leakage and damper the inflammation in diabetic macular edema (DME). The technology targets the 30% DME patients who are poor responders to current anti-VEGF therapies. Maintaining an active role as Board member, advising the CEO.

View
Founder - Ceo

Semathera Inc Sep 2016 - Jun 2018

Westmount, Quebec, Ca

Advisor to CEO from Aug 2017 to Oct 2017. SemaThera is a spin-off company from AmorChem Fund 1, focusing on SEMA 3A inhibitors in the treatment of ocular diseases, especially diabetic macular edema. Technology developed by Dr Mike Sapieha at Hôpital Maisonneuve-Rosemont (HMR).

View
Investor (Former Gp)

Amorchem Sep 2017 - Dec 2022

Westmount, Québec, Ca

Former GP who remained active investor

View
General Partner

Amorchem Mar 2017 - Jan 2021

Westmount, Québec, Ca

General Partner of AmorChem II Ventures, a leading early-stage life science Venture Fund which closed 45.7M$CAD for pre-seed, seed and Series A investments. The fund has the ability to identify disruptive and ground-breaking technologies from universities and turn them into newly-created companies with clear clinical development focus.

View
Entrepreneur In Residence

Amorchem Apr 2016 - Mar 2017

Westmount, Québec, Ca

EIR starting first spin-out companies (Mperia Therapeutics, Corbin Therapeutics, SemaThera and MyX Therapeutics) from AmorChem 1 Ventures portfolio. Remain Chairman of the Board for MyX and SemaThera, and Board observer for Inversago.

View
Board Member - Administrateur

West Island Crisis Centre - Centre De Crise De L'Ouest De L'Île May 2021 - Jun 2022

The West Island Crisis Center’s mission is to meet the needs of adults experiencing a situational crisis, emotional distress, suicidal or otherwise. As well as to bring support to the loved ones of those in crisis. - La mission du Centre de crise de l’Ouest de l’Île est de répondre aux besoins des adultes en état de crise situationnelle, de détresse émotive ou de crise d’adaptation, suicidaire ou non, ainsi qu’à leurs proches.

View
Advisor To Ceo

Neurasic Therapeutics Inc Dec 2020 - May 2021

Montréal, Québec, Ca

View
Executive Chairman, Founder - Ceo

Neurasic Therapeutics Inc Mar 2020 - Dec 2020

Montréal, Québec, Ca

Co-investment made by AmorChem and adMare (CDRD/NeoMed) in an acid-sensing ion channels (ASIC) program, a novel class of pain management drugs, for neuropathy and cancer-inducing pain.

View
Chairman, Board Of Directors

Myx Therapeutics Jun 2018 - Dec 2020

Montreal, Quebec, Ca

Using mucoadhesive nanoparticle drug delivery platform

View
Founder - Ceo

Myx Therapeutics May 2017 - Jun 2018

Montreal, Quebec, Ca

MyX Therapeutics focuses on a mucoadhesive nanoparticle drug delivery platform, mainly for ophthalmic use, now diversifying its use to other applications.

View
Board Observer

Corbin Therapeutics Inc Sep 2018 - Aug 2019

Westmount, Quebec, Ca

Developing inhibitors of USP15 against neuroinflammation

View
Board Member

Corbin Therapeutics Inc Oct 2017 - Sep 2018

Westmount, Quebec, Ca

Former CEO, now Board member advising the CEO. Corbin Therapeutics is a spin-off company from AmorChem Fund 1, developing a sophisticated in-vivo genome-wide screening platform in mice undergoing experimental neuro-inflammation, from the laboratory of Dr Philippe Gros, Faculty of Medicine, McGill University, leading to a novel anti-inflammatory target in the deubiquitinylation (DUB) family of enzymes, more particularly USP15.

View
Founder - Ceo

Corbin Therapeutics Inc Oct 2016 - Oct 2017

Westmount, Quebec, Ca

Corbin Therapeutics is a spin-off company from AmorChem Fund 1, developing a sophisticated in-vivo genome-wide screening platform in mice undergoing experimental neuro-inflammation, from the laboratory of Dr Philippe Gros, Faculty of Medicine, McGill University, leading to a novel anti-inflammatory target in the deubiquitinylation (DUB) family of enzymes. .

View
Board Observer

Mperia Therapeutics Inc Sep 2018 - Aug 2019

Montreal, Quebec, Ca

CD36 receptor technology targeting macrophage-driven inflammation

View
Board Member

Mperia Therapeutics Inc May 2016 - Sep 2018

Montreal, Quebec, Ca

CD36 receptor technology targeting macrophage-driven inflammation

View
Founder - Ceo

Mperia Therapeutics Inc Apr 2016 - Sep 2018

Montreal, Quebec, Ca

Mperia Therapeutics is spin-off company from AmorChem Fund 1, focusing on macrophage-driven inflammation via CD36 receptor immunometabolism. Lead candidates are CD36 receptor cyclic peptides, showing clear efficacy in dry form of age-related macular degeneration (dry AMD) and atherosclerosis models. Technology developed by Prof Huy Ong (Pharmacy) and William Lubell (Chemistry) from University of Montreal.

View
Executive-In-Residence, Bd Life Sciences (Contractual, Part-Time)

Axelys Oct 2015 - Nov 2016

Québec, Quebec, Ca

At the time, it was Gestion Univalor and it became Axelys in 2021. Meeting professors in department and faculties at the University of Montreal. Assisting them with the invention disclosure statements and provisional patent filing. Establishing business relationship between the industry, venture capitalists, entrepreneurs and professors.

View
Consultant, Drug Development Strategy

Gestion Mrim Inc Jun 2013 - Oct 2016

. Laurent Pharmaceuticals (Montreal, Canada) in Phase 2b/3. Inositec (Zurich, Switzerland) acquired by Vifor Pharma (2022). Versantis (Zurich, Switzerland) acquired by Genfit (2022)

View
Founder - Ceo

Gicare Pharma Inc Jul 2011 - Jul 2015

Montreal, Quebec, Ca

gIcare pharma is a clinical-stage, GI specialty company specialized in the development of novel colonic analgesic drugs for the visceral pain management of patients undergoing sedation-free, full colonoscopy. Such colonic analgesic drugs are non-centrally-acting opioid agonist with affinity to kappa and mu opioid receptor, capable of releasing a gaseous mediator, hydrogen sulfide. Financed by co-lead investors, Genesys Capital and Forbion Capital, the Company owns a series of NME and method-of-use patents claiming novel drug salts for the colonoscopy application.

View
Consultant, Drug Development Strategy

Verlyx Pharma Apr 2011 - Jul 2015

Montreal, Quebec, Ca

Formerly Oncozyme Pharma, it became Verlyx. The Company has shifted its activities to liver disease alternatives. Give business and CMC support to Verlyx.

View
Board Member (Foundation)

Suicide Action Montréal Jun 2006 - May 2012

Montréal, Québec, Ca

Board member (2011-2012). Board Observer (Mar 2010 - May 2011). Chairman of the Board (2006-2010). Non-profit / Charity Organization supporting financially Suicide Action Montreal. Main task based on fundraising. Raising annually 250K$+ through local business networking. Responsible for internal policies and corporate governance, in addition to Half-Marathon SAM 2011.

View
Representative, Business Dev.

F.I.S. - Fabbrica Italiana Sintetici S.P.A. Apr 2010 - Feb 2011

Montecchio Maggiore, Vicenza, It

Delmar Chemicals, which became a subsidary of F.I.S. s.p.a (Italy). Authorized representative BD. Delmar Chemicals is a CMO specialized the R-D synthesis and cGMP campaign, including pilot plant scale and commercial production. Synthesis mainly based on small molecules, polymers and excipients. Preparation of DMF (including IV type for new excipients). Analytical development and internal QC testing. Full adherence to cGMP, ICH, JP, Health Canada and FDA requirements.

View
Senior Director, Business Dev.

Kabs Laboratories Inc. Apr 2010 - Jan 2011

Saint-Hubert, Quebec, Ca

Responsible for Global Business Development. KABS Pharmaceutical Services is a CMO offering a wide variety of services, including GLP analytical services, formulation development & cGMP manufacturing, in compliance with ICH and governmental authorities' requirements, including TPD's Health Canada, US FDA and EMEA.

View
Founder - Ceo

Ginova Pharma Oct 2008 - Mar 2010

MERGED WITH NUVECTOR. GInova Pharma Inc is a biotech company specialized in gastrointestinal drug development, including ground-breaking technologies were acquired, including a novel therapeutic approach to treat Celiac diseases, a chronic gluten-induced disorder.
Founder - Ceo

Nuvector Pharma Inc Aug 2007 - Jan 2010

MERGED WITH GINOVA PHARMA, due to common business activities. Nuvector Pharma Inc is a specialized biotech company focusing on innovative polymers, including polymer therapeutics and polymeric micelles in drug delivery. Polymeric Binders as Celiac disease treatment was in-licensed from University of Montreal, technology developed by Prof Jean-Christophe Leroux (now at ETH Zurich)
Associate Director, Cmc/Product Development

Thallion Pharmaceuticals Inc (Tln) Sep 2004 - Dec 2007

Initially Ecopia Biosciences and became Thallion (TSX:TLN) after merger with Caprion Pharmaceuticals Inc, acquired by Bellus Health. Responsible for the formulation development and CMC of 2 i.v. oncology drugs during preclinical & clinical phases. Supervising the outsourced cGMP manufacturing. Meeting with regulatory agencies, IND filings and clinical operating support.

View
Vice-President, Process Development And Manufacturing

Bioxalis Medica Inc May 2003 - Jun 2004

Bioxalis Medica, acquired by Procyon / Ambrilia Pharma. Development of CD-13 targeting liposome using NGR phospholipids and polymer-complex micronized celecoxib. Also includes business development, technology acquisition and due diligence processes.
Director, Research & Innovative Technology

Labopharm Jan 2002 - May 2003

Directing 7 talented scientists specialized in nano-drug delivery. Creation of Labopharm's Nanotechnology arm Focusing on a disruptive micelle technology platform for poorly water-soluble drugs. Labopharm acquired by Paladin (owned by Endo). Responsible for the development of novel taxane-loaded i.v. micelle formulations. In-vitro and in-vivo studies, including antitumor activity study in tumor-bearing mice (human/murine xenograft). Animal proof-of-concept completed.

Maxime Ranger Skills

Drug Development Entrepreneurship Biotechnology Gmp Analytical Chemistry Chemistry Cmc Business Strategy Business Development Clinical Development Private Equity Pharmaceutical Industry Market Intelligence Life Sciences Intellectual Property Strategy

Maxime Ranger Education Details

Stanford University

Material Sciences & Drug Delivery
Université Paris Dauphine - Psl

Business School
École Des Sciences De La Gestion (Esg Uqam)

Esg Business School
Université De Montréal

Pharmaceutical Technology (Drug Delivery)
Université Laval

Materials Sciences (Polymer)
Université De Montréal

Polymer Chemistry
Université De Montréal

Specialized Chemistry

Frequently Asked Questions about Maxime Ranger

What company does Maxime Ranger work for?

Maxime Ranger works for Neurenati

What is Maxime Ranger's role at the current company?

Maxime Ranger's current role is PhD MBA | Startup company creator | Life sciences.

What is Maxime Ranger's email address?

Maxime Ranger's email address is ma****@****dero.vc

What is Maxime Ranger's direct phone number?

Maxime Ranger's direct phone number is +151482*****

What schools did Maxime Ranger attend?

Maxime Ranger attended Stanford University, Université Paris Dauphine - Psl, École Des Sciences De La Gestion (Esg Uqam), Université De Montréal, Université Laval, Université De Montréal, Université De Montréal.

What skills is Maxime Ranger known for?

Maxime Ranger has skills like Drug Development, Entrepreneurship, Biotechnology, Gmp, Analytical Chemistry, Chemistry, Cmc, Business Strategy, Business Development, Clinical Development, Private Equity, Pharmaceutical Industry.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles

Get direct phone numbers & mobile contacts

Access company data & employee information

Works directly on LinkedIn - no copy/paste needed

Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.

Security Check